Abstract
Melamine (2,4,6-triamino-1,3,5-triazine) was first synthesized by Liebig in 1834 and its industrial application, starting with the development of melamine formaldehyde resins in the late 1930ies, has boomed since. In the last 80 years a vast number of different melamine derivatives have been prepared in order to provide structures for applications such as polymers, medicinal drugs, or biologically active compounds. It is the purpose of this review to give an overview on the currently available melamine derivatives and the synthesis strategies leading to their formation.
Keywords: Cyanuric chloride, Melamine, Melamine derivatives, Synthesis, s-Triazines, Triamino-s-triazine
Current Organic Synthesis
Title:Melamine Derivatives - A Review on Synthesis and Application
Volume: 9 Issue: 3
Author(s): Klaus Bretterbauer and Clemens Schwarzinger
Affiliation:
Keywords: Cyanuric chloride, Melamine, Melamine derivatives, Synthesis, s-Triazines, Triamino-s-triazine
Abstract: Melamine (2,4,6-triamino-1,3,5-triazine) was first synthesized by Liebig in 1834 and its industrial application, starting with the development of melamine formaldehyde resins in the late 1930ies, has boomed since. In the last 80 years a vast number of different melamine derivatives have been prepared in order to provide structures for applications such as polymers, medicinal drugs, or biologically active compounds. It is the purpose of this review to give an overview on the currently available melamine derivatives and the synthesis strategies leading to their formation.
Export Options
About this article
Cite this article as:
Bretterbauer Klaus and Schwarzinger Clemens, Melamine Derivatives - A Review on Synthesis and Application, Current Organic Synthesis 2012; 9 (3) . https://dx.doi.org/10.2174/157017912801270612
DOI https://dx.doi.org/10.2174/157017912801270612 |
Print ISSN 1570-1794 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6271 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Sirtuins: An Overview of an Emerging Drug Target in Age-Related Diseases and Cancer
Current Drug Targets Viral Elements Sense Tumorigenic Processes:Approaching Selective Cancer Therapy
Mini-Reviews in Medicinal Chemistry Invasion and Egress by the Obligate Intracellular Parasite Toxoplasma gondii: Potential Targets for the Development of New Antiparasitic Drugs
Current Pharmaceutical Design Lentiviral Transgenesis - A Versatile Tool for Basic Research and Gene Therapy
Current Gene Therapy Optimized Radial Basis Neural Network for Classification of Breast Cancer Images
Current Medical Imaging MicroRNA Gene Networks in Oncogenesis
Current Genomics Meet Our Editorial Board Member:
Current Drug Metabolism Strategies for Targeting IL-4 as a Novel Therapeutic Approach for the Treatment of Atopic Dermatitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Editorial (Thematic Issue: Chemoinformatics Models for Pharmaceutical Design, Part 2)
Current Pharmaceutical Design Editorial [Hot Topic: Beyond Chemotherapy: Future Directions in Lymphoma Treatment (Guest Editor: Thomas Decker)]
Current Drug Targets Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Gene Therapy for Haemophagocytic Lymphohistiocytosis
Current Gene Therapy The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets An Update on Disease Modifying Antirheumatic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Current Pharmaceutical Design Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy
Current Pharmaceutical Design Role of Cytokines in Regulating Feeding Behaviour
Current Drug Targets The Evolving Therapeutic Approaches for Epstein-Barr Virus Infection in Immunocompetent and Immunocompromised Individuals
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Repertoire of Gluten Peptides Active in Celiac Disease Patients: Perspectives For Translational Therapeutic Applications
Endocrine, Metabolic & Immune Disorders - Drug Targets